This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
<i>Staphylococcus</i>	IL-20 receptor- β (IL20R2; IL20RB)	<p>Mouse and cell culture studies suggest inhibiting IL20RB could help treat methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) skin infections. In a mouse model for MRSA skin infection, an anti-IL20RB mAb dosed at the time of infection decreased lesion size compared with a control antibody. In primary human keratinocytes, exposure to MRSA led to greater expression of cytokines that signal via IL20RB than no MRSA exposure. Next steps could include developing small molecule IL20RB inhibitors.</p> <p>SciBX 6(30); doi:10.1038/scibx.2013.796 Published online Aug. 8, 2013</p>	Patent and licensing information unavailable	<p>Myles, I. A. <i>et al. Nat. Immunol.</i>; published online June 23, 2013; doi:10.1038/ni.2637 Contact: Sandip K. Datta, National Institute of Allergy and Infectious Diseases, Bethesda, Md. e-mail: dattas@niaid.nih.gov</p>